KRT78: A Potential Drug Target and Biomarker (G196374)

Target Name: KRT78

NCBI ID: G196374

KRT78

KRT78: A Potential Drug Target and Biomarker

Kallikrein-related peptidases (KRTs) are a family of enzymes that belong to the serine proteases superfamily. These enzymes are involved in the degradation of various peptides, including extracellular matrix (ECM) components, which are essential for tissue regeneration and repair. KRTs have been implicated in a range of physiological processes, including tissue remodeling, embryonic development, and cancer progression. In this article, we will discuss the potential drug target and biomarker properties of KRT78, as well as its current research status and potential future directions.

KRT78: A Potential Drug Target

KRT78 is a 78-kDa protein that is expressed in various tissues, including liver, pancreas, and heart. It is a member of the KRT family and is involved in the degradation of Kallikrein-related peptidases (KRPs), which are a subclass of KRTs that contain a characteristic catalytic center consisting of a tryptophan residue and a lysine residue.

KRT78 has been shown to play a critical role in several physiological processes, including wound healing, tissue remodeling, and cancer progression. For example, KRT78 has been shown to be involved in the regulation of cell proliferation and has been implicated in the development of cancer. Additionally, KRT78 has been shown to play a role in the regulation of inflammation and has been implicated in the pathogenesis of various inflammatory diseases.

Due to its involvement in several important physiological processes, KRT78 has emerged as a potential drug target. Small molecules have been shown to be effective in inhibiting KRT78 activity, which could lead to a reduction in inflammation and cancer progression. Additionally, because KRT78 is also involved in the degradation of extracellular matrix (ECM) components, small molecules that are effective in inhibiting KRT78 activity may also be effective in reducing the appearance of ECM in tissues.

KRT78: A Potential Biomarker

In addition to its potential as a drug target, KRT78 has also been shown to be a potential biomarker for several diseases, including cancer, diabetes, and cardiovascular disease.

KRT78 has been shown to be involved in the regulation of cancer cell proliferation and has been implicated in the development and progression of several types of cancer. For example, studies have shown that KRT78 is involved in the regulation of the growth and survival of cancer cells and has been shown to promote the development of cancer. Additionally, KRT78 has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed in tumors.

KRT78 has also been shown to be involved in the regulation of diabetes and cardiovascular disease. For example, studies have shown that KRT78 is involved in the regulation of insulin sensitivity and has been shown to contribute to the development of type 2 diabetes. Additionally, KRT78 has been shown to be involved in the regulation of blood pressure and has been shown to contribute to the development of cardiovascular disease.

Conclusion

In conclusion, KRT78 is a protein that is involved in several important physiological processes and has been implicated in a range of diseases. Its potential as a drug target and biomarker make it an attractive target for future research and development. Further studies are needed to fully understand the role of KRT78 in these processes and to develop effective small molecules that can inhibit its activity.

Protein Name: Keratin 78

The "KRT78 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRT78 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets